Latest Articles

Publication Date
All News Scientific
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - Defense World

Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan Defense World

Published: Jan. 10, 2026, 6:12 a.m.
Read Full Article
Endometrial Cancer: Evaluating Platinum Re-Challenge Strategies Through the ECHO-EU Lens - OncLive

Endometrial Cancer: Evaluating Platinum Re-Challenge Strategies Through the ECHO-EU Lens OncLive

Published: Jan. 9, 2026, 8:25 p.m.
Read Full Article
Endometrial Cancer: Future Directions - Biomarkers, Sequencing, and Survivorship Priorities - OncLive

Endometrial Cancer: Future Directions - Biomarkers, Sequencing, and Survivorship Priorities OncLive

Published: Jan. 9, 2026, 2:17 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 9, 2026, 6:18 a.m.
Read Full Article
Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data - Nasdaq

Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data Nasdaq

Published: Jan. 8, 2026, 7:14 p.m.
Read Full Article
Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating - TipRanks

Focused Clinical Strategy and Accelerated Approval Path for ACR-368 in High-Need Serous Endometrial Cancer Underpin ACRV Buy Rating TipRanks

Published: Jan. 8, 2026, 7:11 p.m.
Read Full Article
Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe - Nasdaq

Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe Nasdaq

Published: Jan. 8, 2026, 1:42 p.m.
Read Full Article
Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com - Investing.com Australia

Acrivon reports 52% response rate in serous endometrial cancer trial By Investing.com Investing.com Australia

Published: Jan. 8, 2026, 1:10 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 8, 2026, 12:53 p.m.
Read Full Article
Immunotherapy for Advanced Endometrial Cancer - Banner Health

Immunotherapy for Advanced Endometrial Cancer Banner Health

Published: Jan. 8, 2026, 12:51 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!